Literature DB >> 9496392

Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA.

R Adatia1, A Albini, S Carlone, D Giunciuglio, R Benelli, L Santi, D M Noonan.   

Abstract

BACKGROUND: Heparan sulfate proteoglycans are one of the major components of extracellular matrix and are secreted at different levels by several normal and tumoral cells. Perlecan, the basement membrane proteoglycan, has structural domains involved in cell/matrix interactions and growth factor storage. Metastatic melanoma cells show an increase in perlecan expression as compared to low metastatic ones. We examined whether reduction of perlecan expression could down-modulate the malignant phenotype in melanoma clones.
MATERIALS AND METHODS: We transfected B16-F10 murine malignant melanoma cells with a perlecan antisense cDNA construct and tested the in vitro behavior of the selected clones.
RESULTS: The expression of antisense mRNA corresponded to a reduction of perlecan synthesis. The clones with reduced perlecan synthesis showed a down-regulation of proliferation and invasion.
CONCLUSIONS: These results further indicate the importance of perlecan as a regulator of growth factor activity affecting the biological properties of metastatic cells, and suggest the potential use of antisense perlecan DNA in anti-melanoma gene therapy approaches.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9496392     DOI: 10.1023/a:1008243115385

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  21 in total

Review 1.  Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena.

Authors:  R V Iozzo; J D San Antonio
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells.

Authors:  Gui Su; Kristy Meyer; Chilkunda D Nandini; Dianhua Qiao; Shahriar Salamat; Andreas Friedl
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

3.  Tumor attenuation by combined heparan sulfate and polyamine depletion.

Authors:  Mattias Belting; Lubor Borsig; Mark M Fuster; Jillian R Brown; Lo Persson; Lars-Ake Fransson; Jeffrey D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy.

Authors:  Mohammad R Noori-Daloii; Majid Momeny; Mehdi Yousefi; Forough Golsaz Shirazi; Mehdi Yaseri; Nasrin Motamed; Nazanin Kazemialiakbar; Saeed Hashemi
Journal:  Med Oncol       Date:  2010-07-02       Impact factor: 3.064

5.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

6.  Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan.

Authors:  C Marchisone; F Del Grosso; L Masiello; M Prat; L Santi; D M Noonan
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

7.  Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity.

Authors:  Rachel K Okolicsanyi; Andre J van Wijnen; Simon M Cool; Gary S Stein; Lyn R Griffiths; Larisa M Haupt
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

8.  Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion.

Authors:  Fengying Tang; Megan S Lord; William B Stallcup; John M Whitelock
Journal:  J Biochem       Date:  2018-05-01       Impact factor: 3.387

Review 9.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

10.  Evaluation of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents.

Authors:  Vinod Kumar Sanna; Manu Jaggi; Vadlapudi Kumar; Anand C Burman
Journal:  Invest New Drugs       Date:  2009-05-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.